Cathelicidin Peptides Reduce Intestinal Fibrosis in Crohn's Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel diseases, particularly Crohn's disease-associated intestinal fibrosis, are inadequate, with existing therapies focusing on symptom management rather than addressing the underlying fibrosis, and there is a need for non-invasive diagnostic markers and therapeutic agents.
Innovation Solution
The use of cathelicidin peptides, such as LL-37, for diagnosing and treating inflammatory bowel diseases by reducing intestinal fibrosis through intra-colonic and intravenous administration, and increasing cathelicidin levels in patients, which also serves as a biomarker for disease activity and relapse prediction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional medications (antibiotics, aminosalicylates, corticosteroids, immune modifiers, biologic therapies) are administered to treat inflammatory bowel disease, then symptoms of inflammation are reduced, but additional side effects occur (pain, fatigue, digestive problems, skin irritation, increased risk of infection, osteoporosis, etc.)
Solution Approach 1:
The patent utilizes the body's own cathelicidin antimicrobial peptides as the therapeutic agent. By administering recombinant cathelicidin peptides (such as hCAP18/LL-37) or inducing endogenous cathelicidin production, the treatment leverages the patient's inherent immune system components rather than introducing foreign substances, thereby reducing side effects while maintaining anti-inflammatory and antimicrobial efficacy
Solution Approach 2:
The patent changes the therapeutic parameter from conventional anti-inflammatory drugs to cathelicidin peptides with specific antimicrobial and anti-inflammatory properties. This parameter change allows for targeted treatment that addresses both inflammation and microbial factors without the broad-spectrum side effects of traditional medications
2Ease of operation
If current treatment regimes focus on symptom management, then immediate symptoms are alleviated, but the underlying fibrosis and disease progression are not addressed
Solution Approach 1:
The patent employs cathelicidin peptides that not only manage current inflammatory symptoms but also prevent further tissue damage and fibrosis progression. The treatment acts preliminarily to protect against future disease complications by addressing both acute inflammation and chronic fibrotic changes
Solution Approach 2:
Cathelicidin peptides exhibit multiple functions including antimicrobial activity, anti-inflammatory effects, and anti-fibrotic properties. This multi-functionality allows a single therapeutic agent to address symptom management, underlying inflammation, and fibrosis prevention simultaneously
3Measurement precision
If invasive diagnostic procedures are used to diagnose inflammatory bowel disease, then diagnostic accuracy is improved, but patient discomfort and procedural complexity increase
Solution Approach 1:
The patent utilizes cathelicidin peptide levels as a biomarker that can be detected through non-invasive or minimally invasive methods. By measuring cathelicidin concentrations in accessible biological samples, the diagnosis achieves high accuracy without requiring extensive invasive procedures
Solution Approach 2:
The patent introduces cathelicidin peptide measurement as an intermediary diagnostic tool that bridges the gap between non-invasive sampling and accurate disease diagnosis. This biomarker serves as a mediator that provides diagnostic information with minimal patient burden
Data Source
AI summary
Method of diagnosing and treating inflammatory bowel disease are disclosed herein. Inflammatory bowel disease can be treated and diagnosed using cathelicidin peptides and detection agents thereof. Specifically, method of treating and diagnosing Crohn's disease and ulcerative colitis are disclosed herein.